MedTrace Logo

Safety and Feasibility of the NeurolyserXR for Sacroiliac Joint Pain

NCT05396495 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-09-07

No results posted yet for this study

Summary

Pilot study to evaluate the safety and the effectiveness of the Neurolyser XR as a treatment for sacroiliitis

Conditions

  • Sacroiliitis

Interventions

DEVICE

NeurolyserXR

Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint

Sponsors & Collaborators

  • Sheba Medical Center

    collaborator OTHER_GOV

  • FUSMobile Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-24
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05396495 on ClinicalTrials.gov